Advertisement
Screener

KIORA PHARMACEUTICALS, INC. (KPRX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 129.80% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-07

  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 130.20%.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 142.00%, a 1.43% increase year-over-year.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 140.00%, a 3.45% decline year-over-year.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 145.00%, a 6.45% decline year-over-year.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 140.00%, a 0.00% change from fiscal 2021.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 140.00%, a 8.50% decline from fiscal 2020.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 153.00%, a 0.66% increase from fiscal 2019.
  • KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 152.00%, a 3.80% decline from fiscal 2018.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2026-06-30129.80%
10-Q · filed 2026-08-07
2026-03-31130.20%
10-Q · filed 2026-05-08
2025-09-30136.60%
10-Q · filed 2025-11-07
2025-06-30136.60%
10-Q · filed 2026-08-07
2024-09-30140.00%
10-Q · filed 2025-11-07
2023-09-30141.00%
10-Q · filed 2024-11-08
2023-06-30142.00%
10-Q · filed 2024-08-09
2023-03-31142.00%
10-Q · filed 2024-05-10
2022-12-31140.00%
10-K · filed 2024-03-25
2022-09-30140.00%
10-Q · filed 2023-11-09
2022-06-30140.00%
10-Q · filed 2023-08-08
2022-03-31140.00%
10-Q · filed 2023-05-09
2021-12-31140.00%
10-K · filed 2023-03-23
2021-09-30141.00%
10-Q · filed 2022-11-09
140.00%
10-Q · filed 2021-11-15
2021-06-30141.00%
10-Q · filed 2022-08-12
2021-03-31145.00%
10-Q · filed 2021-05-12
2020-12-31153.00%
10-K/A · filed 2022-07-07
2020-09-30153.00%
10-Q · filed 2021-11-15
2020-06-30153.00%
10-Q · filed 2021-08-12
2020-03-31155.00%
10-Q · filed 2021-05-12
2019-12-31152.00%
10-K · filed 2021-03-25
2019-09-30152.00%
10-Q · filed 2020-11-09
2019-06-30152.00%
10-Q · filed 2020-08-06
2019-03-31152.00%
10-Q · filed 2020-05-06
2018-12-31158.00%
10-K · filed 2020-03-04
2018-09-30158.00%
10-Q · filed 2019-11-07
2018-06-30159.00%
10-Q · filed 2019-08-08
2018-03-31159.00%
10-Q · filed 2019-05-08
2017-12-31170.00%
10-K · filed 2019-03-01
2017-09-30171.00%
10-Q · filed 2018-11-13
2017-06-30172.00%
10-Q · filed 2018-08-03
2017-03-31174.00%
10-Q · filed 2018-05-11
2016-12-3199.00%
10-K · filed 2018-03-02
2016-09-3065.00%
10-Q · filed 2017-11-14
2016-06-3065.00%
10-Q · filed 2017-08-04
2016-03-3165.00%
10-Q · filed 2017-05-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
BIOVIE INC. (BIVI)United States$0.012B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33